Elizabeth J Tarling1, Hannah Ahn1, Thomas Q de Aguiar Vallim2. 1. From the Division of Cardiology, Departments of Medicine (E.J.T., H.A., T.Q.d.A.V.), and The Molecular Biology Institute (E.J.T.), University of California, Los Angeles. 2. From the Division of Cardiology, Departments of Medicine (E.J.T., H.A., T.Q.d.A.V.), and The Molecular Biology Institute (E.J.T.), University of California, Los Angeles. tvallim@mednet.ucla.edu.
Abstract
OBJECTIVE: To determine whether activation of farnesoid X receptor (FXR) alters cellular and plasma cholesterol homeostasis as a result of regulation of Srebp-2 and miR-33. APPROACH AND RESULTS: Chromatin immunoprecipitation sequencing data identified an FXR response element within intron 10 of the Srebp-2 gene. Consistent with this observation, treatment of mice with FXR-specific agonists (GSK2324 or GW4064) rapidly increased hepatic levels of Srebp-2 mRNA, precursor sterol response element binding protein 2 (pSREBP-2) protein, and miR-33. Furthermore, miR-33 targets, that include ABCA1 (ATP binding cassette transporter A1), NSF (N-ethylmaleimide-sensitive factor), and CPT1 (carnitine palmitoyltransferase 1), were all reduced in GSK2324-treated mice. In contrast, neither nuclear SREBP-2 protein (nSREBP-2) nor SREBP-2 target genes were induced after FXR activation. The inability to process pSREBP-2 to nSREBP-2 is likely a consequence of the induction of insulin INSIG-2A (induced gene 2A) by FXR agonists. Finally, we show that FXR-dependent induction of both Srebp-2 and miR-33 is ablated in Scap(-/-) mice that lack nuclear SREBP-2. CONCLUSIONS: We demonstrate that the activation of FXR uncouples the expression of nuclear SREBP-2 and miR-33, and the regulation of their respective target genes. Further, we conclude that the FXR agonist-dependent increase in miR-33 requires transcription of the Srebp-2 gene.
OBJECTIVE: To determine whether activation of farnesoid X receptor (FXR) alters cellular and plasma cholesterol homeostasis as a result of regulation of Srebp-2 and miR-33. APPROACH AND RESULTS: Chromatin immunoprecipitation sequencing data identified an FXR response element within intron 10 of the Srebp-2 gene. Consistent with this observation, treatment of mice with FXR-specific agonists (GSK2324 or GW4064) rapidly increased hepatic levels of Srebp-2 mRNA, precursor sterol response element binding protein 2 (pSREBP-2) protein, and miR-33. Furthermore, miR-33 targets, that include ABCA1 (ATP binding cassette transporter A1), NSF (N-ethylmaleimide-sensitive factor), and CPT1 (carnitine palmitoyltransferase 1), were all reduced in GSK2324-treated mice. In contrast, neither nuclear SREBP-2 protein (nSREBP-2) nor SREBP-2 target genes were induced after FXR activation. The inability to process pSREBP-2 to nSREBP-2 is likely a consequence of the induction of insulin INSIG-2A (induced gene 2A) by FXR agonists. Finally, we show that FXR-dependent induction of both Srebp-2 and miR-33 is ablated in Scap(-/-) mice that lack nuclear SREBP-2. CONCLUSIONS: We demonstrate that the activation of FXR uncouples the expression of nuclear SREBP-2 and miR-33, and the regulation of their respective target genes. Further, we conclude that the FXR agonist-dependent increase in miR-33 requires transcription of the Srebp-2 gene.
Authors: M Matsuda; B S Korn; R E Hammer; Y A Moon; R Komuro; J D Horton; J L Goldstein; M S Brown; I Shimomura Journal: Genes Dev Date: 2001-05-15 Impact factor: 11.361
Authors: Jonathan Y Bass; Justin A Caravella; Lihong Chen; Katrina L Creech; David N Deaton; Kevin P Madauss; Harry B Marr; Robert B McFadyen; Aaron B Miller; Wendy Y Mills; Frank Navas; Derek J Parks; Terrence L Smalley; Paul K Spearing; Dan Todd; Shawn P Williams; G Bruce Wisely Journal: Bioorg Med Chem Lett Date: 2010-12-23 Impact factor: 2.823
Authors: Hansook Kim Chong; Aniello M Infante; Young-Kyo Seo; Tae-Il Jeon; Yanqiao Zhang; Peter A Edwards; Xiaohui Xie; Timothy F Osborne Journal: Nucleic Acids Res Date: 2010-05-18 Impact factor: 16.971
Authors: Brian J Bennett; Thomas Q de Aguiar Vallim; Zeneng Wang; Diana M Shih; Yonghong Meng; Jill Gregory; Hooman Allayee; Richard Lee; Mark Graham; Rosanne Crooke; Peter A Edwards; Stanley L Hazen; Aldons J Lusis Journal: Cell Metab Date: 2013-01-08 Impact factor: 27.287
Authors: Thomas Q de Aguiar Vallim; Elizabeth J Tarling; Tammy Kim; Mete Civelek; Ángel Baldán; Christine Esau; Peter A Edwards Journal: Circ Res Date: 2013-03-21 Impact factor: 17.367
Authors: Guodong Li; Ann M Thomas; Jessica A Williams; Bo Kong; Jie Liu; Yuka Inaba; Wen Xie; Grace L Guo Journal: PLoS One Date: 2012-04-23 Impact factor: 3.240
Authors: Cristina M Ramírez; Noemi Rotllan; Alexander V Vlassov; Alberto Dávalos; Mu Li; Leigh Goedeke; Juan F Aranda; Daniel Cirera-Salinas; Elisa Araldi; Alessandro Salerno; Amarylis Wanschel; Jiri Zavadil; Antonio Castrillo; Jungsu Kim; Yajaira Suárez; Carlos Fernández-Hernando Journal: Circ Res Date: 2013-03-21 Impact factor: 17.367
Authors: Laurent Vergnes; Robert G Chin; Thomas de Aguiar Vallim; Loren G Fong; Timothy F Osborne; Stephen G Young; Karen Reue Journal: J Lipid Res Date: 2015-12-18 Impact factor: 5.922
Authors: Elizabeth J Tarling; Bethan L Clifford; Joan Cheng; Pauline Morand; Angela Cheng; Ellen Lester; Tamer Sallam; Martin Turner; Thomas Q de Aguiar Vallim Journal: J Clin Invest Date: 2017-09-11 Impact factor: 19.456
Authors: Pablo Letelier; Ismael Riquelme; Alfonso H Hernández; Neftalí Guzmán; Jorge G Farías; Juan Carlos Roa Journal: Int J Mol Sci Date: 2016-05-23 Impact factor: 5.923